Miragen Therapeutics – Consensus Indicates Potential 111.1% Upside

Broker Ratings

Miragen Therapeutics found using ticker (MGEN) now have 4 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 75 and 18 with the average target price sitting at 41. Now with the previous closing price of 19.42 this is indicating there is a potential upside of 111.1%. The 50 day MA is 17.73 and the 200 day moving average is 15.05. The company has a market capitalisation of $75m. Company Website: http://www.miragen.com

Miragen Therapeutics, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics was founded in 2006 and is based in Boulder, Colorado.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp